Ireland has evolved into one of the world’s most critical locations for the global Pharmaceutical Industry. Today, with more than 90 FDA-approved facilities, 50,000 people employed in the sector, and more than $133 billion in annual pharmaceutical exports, the country combines stability, world-class talent and an integrated global supply chain which ensures the uninterrupted supply of life-saving medicines for patients around the world. During a period of great volatility, Ireland remains a stable and trusted partner for the global pharmaceutical industry.

A 60-year foundation of reliability and regulatory excellence

Ireland’s leadership position in the global pharmaceutical industry is no accident. In the late 1960s, Ireland made a strategic decision to open itself to global industry. Early pharmaceutical investors such as Pfizer in Ringaskiddy and Merck in Ballydine, among others, chose Ireland for small-molecule manufacturing because of a location with strong access to the European market, a financially attractive and efficient operating base and a stable policy environment, factors which continue to underpin Ireland’s position as a global Biopharmaceutical manufacturing location of choice today. These sites, along with many others, continue to thrive in small molecule manufacturing. In Ireland today, there are now 50 sites manufacturing Active Pharmaceutical Ingredients and drug products being exported around the world.

In the decades since, Ireland has built a track record of regulatory excellence that few regions have matched. With more than 90 FDA-approved plants, Industry leaders know their life-saving products will be manufactured safely, consistently, and compliantly. FDA inspections in Ireland routinely reaffirm that confidence. In an industry where patient safety comes first and compliance can never be compromised, Ireland has become a trusted, dependable manufacturing base.

Where capital investment is accelerating

Built on the foundation of the country’s small molecule manufacturing expertise, the rise of biologics drugs ushered in a new wave of manufacturing investment, primarily large-scale monoclonal antibody drug substance manufacturing. Beginning in the early 1980’s, Ireland’s first Biotech plant was opened by Shering-Plough (now MSD) investing in Brinny, Co. Cork. Since then, large molecule manufacturing has grown rapidly and in the last decade alone, Ireland has secured €15 billion in new biopharma investment. For instance, Lilly is investing $2 billion in a new Biologics facility in Limerick to build a fully integrated digital site with the latest machine automation, manufacturing execution, and data technologies. This is in addition to an $800 million investment in their Kinsale facility. Pfizer is in the midst of a $1.26 billion investment, expanding its biologics capacity in Dublin, and in 2021, AstraZeneca announced a $350 million investment in high-potency small-molecule manufacturing due to be completed this year, in Dublin.

More recently, and in exciting news for patients interested in weight loss, Novo Nordisk announced an investment of 432 million euro in its manufacturing operations in Monksland, Althlone, Ireland. This tableting facility will provide significant additional capacity for current and future Novo Nordisk GLP-1 treatments.

A deep, specialized talent pool

The depth and experience of Ireland’s pharmaceutical workforce continues to be one of the country’s defining advantages. Ireland is home to one of the world’s largest concentrations of biopharma manufacturing professionals, many of whom have spent their entire careers working in Good Manufacturing Practice (GMP) environments, combining decades of technical expertise with a culture of excellence that consistently delivers for the global pharmaceutical industry.

To develop the next generation of biopharmaceutical manufacturing capabilities, Ireland has invested in world class Institutions like NIBRT, the National Institute for Bioprocessing Research and Training. NIBRT trains thousands of individuals each year using real-world bioprocessing equipment, effectively acting as a “flight simulator” for biotech manufacturing. Their early investment in biologics training positioned Ireland ahead of the rapid expansion of monoclonal antibody production and has proven to be a transformative force for the industry.

Now, NIBRT has expanded into cell and gene therapy training, preparing Ireland for the next wave of therapeutic innovations. As ATMPs (advanced therapy medicinal products) progress through clinical pipelines, this expansion will ensure that Ireland’s talent pool keep pace with the next wave of modalities.

Futureproofing through national infrastructure investment

One of the most significant developments for Ireland’s long‑term competitiveness is the government’s 2025 announcement of a major national commitment to invest $216 billion in national infrastructure by 2035. This comprehensive program spans transport, utilities, energy, and housing, and represents one of the most substantial investments in the State’s history. It underscores Ireland’s sustained dedication to building the resilient foundation required to support the continued growth of the biopharmaceutical sector.

For an ecosystem as advanced, specialized, and interconnected as Irelands, robust national infrastructure is critical for maintaining operational excellence, supply chain reliability, and the environmental performance expected of a global life sciences hub. This long‑term investment strategy ensures that Ireland remains well positioned to facilitate capital‑intensive projects, accommodate energy‑intensive manufacturing, and attract and retain the life sciences investments of the future.

Sustainability and innovation transformation

Sustainability and innovation are moving in parallel and reshaping how life‑sciences companies operate in Ireland. Ireland is famous for being green, but from an energy standpoint, it is green and the direction is clear and measurable: renewables supplied about 41% of Ireland’s electricity in 2023, and 40% in 2024, with wind providing the bulk of that generation. These levels give manufacturers a practical route to lower‑carbon power without stepping away from industrial scale.

Innovation policy is also advancing and is part of the same transformational agenda for Ireland’s Pharmaceutical industry. Ireland’s R&D Tax Credit has recently risen to 35%, a 10% rise since 2023, reinforcing Ireland’s competitiveness and commitment to innovation. Alongside the tax credit, IDA Ireland’s RD&I grants provide additional incentives for companies to invest in R&D, ensuring a major economic support routinely in the range of 45 – 50% support for large-scale, multi-year, innovation project.

Taken together, these shifts amount real change for the pharma industry in Ireland. Cleaner, more sustainable energy that supports large scale industrial development, and a policy framework that rewards innovation, critical enablers for an industry as complex, capital intensive and research focused as the pharmaceutical industry.

Trade environment creates new opportunities

While Pharmaceutical companies are increasing U.S. manufacturing, that shift does not diminish Ireland’s role. In fact, the complexity of pharmaceutical supply chains means companies need multiple, redundant manufacturing sources to protect against disruption and supply global markets.

Ireland remains a trusted location for that redundancy and for manufacturing products bound for Europe’s population of more than 744 million citizens, in addition to global non-US markets around the world. As companies evaluate their network strategy in this new trade environment, Ireland’s infrastructure, expertise, and compliance track record make it one of the most compelling options.

Truster partner in a changing world

Ireland’s leadership position is not the result of a single cycle or a short run of investment. It has been built deliberately over time, through a combination of governmental policy, proven delivery, a deep pool of talent, and an ecosystem that works on the global scale. In a time of profound change, from supply chain pressures to shifting market dynamics, that kind of consistency is a strategic advantage. For companies, it means having a place where long-term decisions can be made with confidence and where operations can run reliably day after day. For patients, it means something even more important, a steady, dependable flow of life-saving medicines when and where they are needed.